FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 339:346-347 July 30, 1998 Number 5 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited Related Article by Krum, H. PubMed Citation

To the Editor: Krum and colleagues (March 19 issue)¹ make the clinically important observation that the orally active endothelin ET_A- and ET_B-receptor antagonist bosentan causes a sustained reduction of blood pressure in patients with essential hypertension. Although the study was carefully designed and performed, we have some issues of concern related to the interpretation of the results.

First, the authors state that the reduction in blood pressure brought about by bosentan suggests that endothelin-1 contributes to the elevation of blood pressure in patients with essential hypertension, implying causation. However, as the authors note, this study did not test . . . [Full Text of this Article]

References

This article has been cited by other articles:

• Martin, P., Ninio, D., Krum, H. (2002). Effect of Endothelin Blockade on Basal and Stimulated Forearm Blood Flow in Patients With Essential Hypertension. Hypertension 39: 821-824 [Abstract] [Full Text]  
• Haylor, J. L., Morcos, S. K. (2001). An oral ETA-selective endothelin receptor antagonist for contrast nephropathy?. Nephrol Dial Transplant 16: 1336-1337 [Full Text]